==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb

This page displays user query in tabular form.

1075 details
Primary information
ThPP IDTh1013
Therapeutic Peptide/Protein NameEpoetin alfa
SequenceAPPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYA view full sequnce in fasta
Functional ClassificationIb
Molecular Weight18396.1
Chemical FormulaC815H1317N233O241S5
Isoelectric Point8.75
HydrophobicityN.A.
Melting Point (℃)53
Half LifeN.A.
DescriptionIt is recombinant human erythropoietin which is produced by CHO cells.
Indication/DiseaseFor treatment of anemia (from renal transplants or certain HIV treatment).
PharmacodynamicsUsed in the treatment of anemia and involved in the regulation of erythrocyte differentiation and maintenance of a physiological level of circulating erythrocyte mass.
Mechanism of ActionBinding of erythropoietin to the erythropoietin receptor leads to receptor dimerization which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameEpofit
CompanyIntas pharma
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearnceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID20369312, 18208642
3-D StructureTh1013 (View) or (Download)